Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#121 / 200 Total
FFIE - Faraday Future Intelligent Electric Inc - Stock Price Chart
TickerFFIE [NASD]
CompanyFaraday Future Intelligent Electric Inc
CountryUSA
IndustryAuto Manufacturers
Market Cap47.60MEPS (ttm)-122.17
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S88.15EPS next 5Y-
P/B0.21EPS Q/Q98.89%
Dividend-Sales Q/Q-98.37%
Insider Own8.93%Inst Own1.16%
Insider Trans-0.41%Inst Trans192.96%
Short Float17.92%EarningsAug 20/a
Analyst Recom3.00Target Price96000.00
Avg Volume8.15M52W Range0.99 - 156.00
Faraday Future Intelligent Electric, Inc. is an emerging growth company, which manufactures electric vehicles. The company was founded by Jia Yueting in May 2014 and is headquartered in Gardena, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen ChadDirectorNov 25 '24Sale1.5715,00023,5507,943Nov 26 06:33 PM
Chen ChadDirectorOct 14 '24Option Exercise0.0022,557022,943Oct 18 04:16 PM
Peker LevDirectorOct 14 '24Option Exercise0.0022,557022,811Oct 18 04:14 PM
Sheng JieDirectorOct 14 '24Option Exercise0.0022,557022,937Oct 18 04:12 PM
Aydt MatthiasGlobal Chief Exec. OfficerJun 21 '24Buy100.0011001Jun 25 04:11 PM
OMER - Omeros Corporation - Stock Price Chart
TickerOMER [NASD, RUT]
CompanyOmeros Corporation
CountryUSA
IndustryBiotechnology
Market Cap643.53MEPS (ttm)-2.30
P/E-EPS this Y-55.14%
Forward P/E-EPS next Y16.00%
PEG-EPS past 5Y6.37%
P/S-EPS next 5Y-
P/B-EPS Q/Q7.39%
Dividend-Sales Q/Q-
Insider Own4.46%Inst Own43.65%
Insider Trans0.00%Inst Trans0.90%
Short Float19.37%EarningsNov 13/a
Analyst Recom2.33Target Price9.00
Avg Volume679.98K52W Range2.22 - 12.49
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
KRRO - Korro Bio Inc - Stock Price Chart
TickerKRRO [NASD, RUT]
CompanyKorro Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap465.79MEPS (ttm)-12.02
P/E-EPS this Y82.53%
Forward P/E-EPS next Y-5.10%
PEG-EPS past 5Y-11.67%
P/S-EPS next 5Y-
P/B2.58EPS Q/Q85.65%
Dividend-Sales Q/Q-
Insider Own40.87%Inst Own59.03%
Insider Trans-0.30%Inst Trans2.56%
Short Float4.40%EarningsNov 12/a
Analyst Recom1.00Target Price133.83
Avg Volume120.29K52W Range30.00 - 98.00
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Agarwal VineetChief Financial OfficerNov 11 '24Option Exercise11.688009,344800Nov 12 07:40 PM
Agarwal VineetChief Financial OfficerNov 11 '24Sale70.0080056,0000Nov 12 07:40 PM
Agarwal VineetOfficerNov 11 '24Proposed Sale70.0080056,000Nov 12 08:28 AM
Agarwal VineetChief Financial OfficerOct 17 '24Option Exercise11.9910,216122,46810,216Oct 18 07:43 PM
Agarwal VineetChief Financial OfficerOct 17 '24Sale78.2610,216799,5270Oct 18 07:43 PM
AXTI - AXT Inc - Stock Price Chart
TickerAXTI [NASD]
CompanyAXT Inc
CountryUSA
IndustrySemiconductor Equipment & Materials
Market Cap91.96MEPS (ttm)-0.24
P/E-EPS this Y60.00%
Forward P/E-EPS next Y64.71%
PEG-EPS past 5Y-
P/S0.97EPS next 5Y20.00%
P/B0.47EPS Q/Q49.78%
Dividend-Sales Q/Q36.16%
Insider Own6.91%Inst Own48.59%
Insider Trans0.00%Inst Trans-1.58%
Short Float1.49%EarningsOct 31/a
Analyst Recom1.00Target Price5.20
Avg Volume338.81K52W Range1.73 - 5.64
AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.
BWEN - Broadwind Inc - Stock Price Chart
TickerBWEN [NASD]
CompanyBroadwind Inc
CountryUSA
IndustrySpecialty Industrial Machinery
Market Cap41.35MEPS (ttm)0.14
P/E12.99EPS this Y-94.44%
Forward P/E10.11EPS next Y825.00%
PEG0.54EPS past 5Y-
P/S0.26EPS next 5Y24.00%
P/B0.70EPS Q/Q-98.33%
Dividend-Sales Q/Q-37.89%
Insider Own11.56%Inst Own28.14%
Insider Trans0.18%Inst Trans-1.79%
Short Float0.89%EarningsNov 13/b
Analyst Recom1.00Target Price4.19
Avg Volume155.10K52W Range1.52 - 4.65
Broadwind, Inc. engages in the manufacture of structures, equipment, and components for clean tech and other specialized applications. It operates through the following business segments: Heavy Fabrications, Gearing, and Industrial Solutions. The Heavy Fabrications segment provides fabrications to customers in industrial markets. The Gearing segment provides gearing, gearboxes, and precision machined components to customers in onshore and offshore oil and gas (O&G) fracking and drilling, surface and underground mining, wind energy, steel, material handling and other industrial markets. The Industrial Solutions segment provides supply chain solutions, light fabrication, inventory management, and kitting and assembly services, primarily serving the combined cycle natural gas turbine market. Broadwind was founded in 1996 and is headquartered in Cicero, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blashford Eric B.President and CEOAug 16 '24Buy2.275,00011,340468,487Aug 20 05:02 PM
Schueller Daniel E.Pres., Broadwind Heavy Fab.May 28 '24Sale4.535,80026,284146,694May 30 05:32 PM
NKTX - Nkarta Inc - Stock Price Chart
TickerNKTX [NASD, RUT]
CompanyNkarta Inc
CountryUSA
IndustryBiotechnology
Market Cap199.00MEPS (ttm)-1.87
P/E-EPS this Y25.06%
Forward P/E-EPS next Y0.83%
PEG-EPS past 5Y-209.81%
P/S-EPS next 5Y-
P/B0.46EPS Q/Q26.29%
Dividend-Sales Q/Q-
Insider Own34.82%Inst Own68.87%
Insider Trans-0.03%Inst Trans3.62%
Short Float14.72%EarningsNov 07/a
Analyst Recom1.00Target Price16.29
Avg Volume841.58K52W Range2.38 - 16.24
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hager Alicia J.Chief Legal OfficerJul 16 '24Sale8.003,39627,168103,819Jul 18 04:22 PM
Trager JamesChief Scientific OfficerJun 18 '24Sale5.604562,554150,959Jun 20 05:04 PM
HASTINGS PAUL JChief Executive OfficerJun 18 '24Sale5.601,7709,912240,737Jun 20 05:03 PM
Shook DavidChief Medical OfficerJun 18 '24Sale5.604562,554116,524Jun 20 05:03 PM
Hager Alicia J.Chief Legal OfficerJun 18 '24Sale5.607274,071107,215Jun 20 05:02 PM
YMAB - Y-Mabs Therapeutics Inc - Stock Price Chart
TickerYMAB [NASD, RUT]
CompanyY-Mabs Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap491.78MEPS (ttm)-0.54
P/E-EPS this Y-28.44%
Forward P/E-EPS next Y8.89%
PEG-EPS past 5Y20.06%
P/S5.82EPS next 5Y-
P/B5.32EPS Q/Q11.71%
Dividend-Sales Q/Q-9.74%
Insider Own16.99%Inst Own60.15%
Insider Trans-2.81%Inst Trans6.69%
Short Float9.77%EarningsNov 08/b
Analyst Recom1.55Target Price20.91
Avg Volume244.50K52W Range6.05 - 20.90
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasCHIEF BUSINESS OFFICERSep 19 '24Option Exercise4.3822,831100,000181,531Sep 20 04:15 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 13 '24Sale13.4765,000875,55097,681Sep 17 08:05 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 16 '24Sale12.9730,000389,10067,681Sep 17 08:05 PM
Thomas GadOfficerSep 13 '24Proposed Sale13.74100,0001,374,000Sep 13 04:19 PM
Ber GerardDirectorSep 03 '24Proposed Sale13.8313,950192,928Sep 03 05:00 PM
ALLO - Allogene Therapeutics Inc - Stock Price Chart
TickerALLO [NASD, RUT]
CompanyAllogene Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap497.97MEPS (ttm)-1.56
P/E-EPS this Y36.48%
Forward P/E-EPS next Y-1.50%
PEG-EPS past 5Y22.18%
P/S12449.19EPS next 5Y1.00%
P/B1.07EPS Q/Q13.34%
Dividend-Sales Q/Q-100.00%
Insider Own32.07%Inst Own68.24%
Insider Trans-0.04%Inst Trans-0.60%
Short Float24.61%EarningsNov 07/a
Analyst Recom1.53Target Price9.73
Avg Volume2.19M52W Range1.99 - 5.78
Nov-25-24 12:00PM Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why (Zacks)
Nov-19-24 08:30AM Allogene Therapeutics Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-18-24 08:30AM Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence (GlobeNewswire) -5.29%
Nov-08-24 06:07AM Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... (GuruFocus.com)
Nov-07-24 04:11PM Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
10:00AM Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS (GlobeNewswire)
Nov-06-24 07:31AM Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +7.69%
Nov-05-24 09:10AM Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-24 08:30AM Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +10.29%
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Humer Franz BDirectorDec 03 '24Proposed Sale2.489,22122,868Dec 02 02:11 PM
Parker Geoffrey M.OfficerOct 21 '24Proposed Sale2.8436,404103,501Oct 21 04:05 PM
Douglas Earl MartinOfficerAug 21 '24Proposed Sale2.7928,31078,844Aug 21 04:18 PM
MESSEMER DEBORAH M.DirectorJun 18 '24Sale2.2818,64142,488166,765Jun 20 04:31 PM
Humer Franz BDirectorMay 30 '24Sale2.3411,20026,181255,253Jun 03 04:09 PM
MNMD - Mind Medicine Inc - Stock Price Chart
TickerMNMD [NASD, RUT]
CompanyMind Medicine Inc
CountryUSA
IndustryBiotechnology
Market Cap555.85MEPS (ttm)-2.09
P/E-EPS this Y40.94%
Forward P/E-EPS next Y1.46%
PEG-EPS past 5Y2.29%
P/S-EPS next 5Y-
P/B2.36EPS Q/Q39.12%
Dividend-Sales Q/Q-
Insider Own3.25%Inst Own-
Insider Trans-2.86%Inst Trans34.86%
Short Float36.90%EarningsNov 07/a
Analyst Recom1.12Target Price26.62
Avg Volume1.10M52W Range2.92 - 12.22
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sullivan, MarkOfficerSep 25 '24Proposed Sale5.984,43026,487Sep 25 08:31 PM
Liao CarrieChief Accounting OfficerSep 25 '24Sale5.982,35214,06599,543Sep 25 08:30 PM
Barrow RobertChief Executive OfficerSep 25 '24Sale5.9819,771118,231545,772Sep 25 08:29 PM
Karlin, DanOfficerSep 25 '24Proposed Sale5.986,87141,081Sep 25 08:29 PM
Karlin DanChief Medical OfficerSep 25 '24Sale5.986,87141,089344,656Sep 25 08:29 PM
STXS - Stereotaxis Inc - Stock Price Chart
TickerSTXS [AMEX, RUT]
CompanyStereotaxis Inc
CountryUSA
IndustryMedical Instruments & Supplies
Market Cap191.91MEPS (ttm)-0.27
P/E-EPS this Y0.93%
Forward P/E-EPS next Y28.97%
PEG-EPS past 5Y-60.95%
P/S7.63EPS next 5Y-
P/B17.74EPS Q/Q-9.83%
Dividend-Sales Q/Q17.91%
Insider Own17.52%Inst Own48.37%
Insider Trans0.11%Inst Trans0.91%
Short Float4.39%EarningsNov 11/a
Analyst Recom1.00Target Price4.50
Avg Volume270.98K52W Range1.58 - 3.29
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Isaac Paul JDirectorAug 19 '24Buy1.888121,5272,767,626Aug 21 08:32 AM
Isaac Paul JDirectorAug 20 '24Buy1.884428312,768,068Aug 21 08:32 AM
Isaac Paul JDirectorAug 15 '24Buy1.908,09515,3502,766,814Aug 20 08:38 PM
Isaac Paul JDirectorJun 14 '24Buy1.867,00013,0172,765,719Jun 17 04:00 PM
Isaac Paul JDirectorMay 31 '24Buy1.961,0001,9582,758,719Jun 04 10:45 AM
18910111213141516171820